FutureDx Summit 2026 · AMR Diagnostics
Put Your AMR Diagnostics in Front of NHS Buyers
FutureDx Summit 2026 brings the microbiologists, infection specialists, and lab directors who shape AMR testing into one validated room. Reach the people who decide what the NHS uses against resistance.
P.S. Rapid susceptibility, molecular resistance, stewardship, or point-of-care, if it fights resistance, your buyers are here.
No instant download. A senior member of the team replies personally.
The AMR Conference Track at FutureDx Summit 2026
FutureDx Summit 2026 includes a dedicated AMR conference track covering antimicrobial resistance detection, rapid resistance testing and stewardship. It runs on 27–28 October 2026 in London, alongside the wider infectious disease diagnostics programme.
The AMR sessions bring together NHS Consultant Microbiologists, infection specialists, AMR stewardship leads and UKHSA scientists with the companies building resistance diagnostics.
Why now
AMR Is Climbing the NHS Priority List
Three forces are pushing antimicrobial resistance up the agenda, and all three create demand for better diagnostics.
Resistance Is Rising
More infections fail first-line antibiotics, and the NHS needs better tools to detect and respond.
Stewardship Is a Priority
Trusts are under pressure to use antibiotics precisely, which means testing before they prescribe.
Speed Saves
Clinicians need resistance answers in hours, not days, driving real demand for rapid diagnostics.
Agenda fit
AMR Runs Through the Whole Programme
This is not a single side session. Resistance is woven across the agenda your buyers came for.
Rapid Susceptibility Testing
Faster antimicrobial susceptibility results to guide treatment and stewardship.
Molecular Resistance Detection
Genotypic detection of resistance markers at speed.
Antimicrobial Stewardship
Using diagnostics to protect antibiotics and prescribe precisely.
Sepsis and AMR
Rapid diagnosis where resistance is most dangerous.
Genomic Surveillance
Tracking resistance across populations and settings.
Point-of-Care Resistance Testing
Resistance decisions made closer to the patient.
The buyers
Who Decides on AMR Diagnostics
An AMR purchase is a committee decision. FutureDx puts the whole committee in one room.
The room
Senior, Validated, and On-Topic
A small room, but the right one: the people who actually decide what the NHS uses against resistance.
Delegate Seniority
The Whole AMR Committee, In One Place
An AMR diagnostic rarely gets bought by one person. The microbiologist who recommends it, the stewardship lead who needs it, the lab director who funds it, and the scientist who validates it are all in the room, and with pre-arranged meetings you can reach them in two days. See how the 1:1 meetings programme works.
Questions
AMR Sponsorship, Answered
Is AMR really on the FutureDx agenda?
Yes. Antimicrobial resistance runs through the programme, from rapid antimicrobial susceptibility testing and molecular resistance detection to antimicrobial stewardship, the sepsis and AMR overlap, genomic surveillance, and point-of-care resistance testing. It is one of the core themes the audience comes for.
Who attends that is relevant to AMR diagnostics?
The people who decide what the NHS uses against resistance: consultant microbiologists, infection and ID consultants, antimicrobial stewardship leads, lab directors and heads of pathology, molecular clinical scientists, and UKHSA and public health leads. More than 60% are at VP level and above and every delegate is validated before they register.
Why sponsor an AMR-focused event now?
Resistance is rising, antimicrobial stewardship is a growing NHS priority, and clinicians need faster resistance results to treat correctly and protect antibiotics. That combination is driving real demand for AMR diagnostics, so the buyers are actively looking for better tools.
My product is in rapid susceptibility testing. Is this the right room?
Yes. Rapid antimicrobial susceptibility testing, molecular resistance panels, stewardship software, and point-of-care resistance tests all map directly onto the agenda and the audience. You will be in front of the microbiologists and stewardship leads who evaluate and adopt them.
How do we get in front of the AMR audience?
Through a sponsorship package or the standalone 1:1 Meetings programme. Each tier includes a set number of pre-arranged meetings, so you can book time with the specific microbiologists, stewardship leads, and lab directors you want to reach. Request the AMR sponsor pack for the options and pricing.
It is the inaugural edition. Is it worth it for AMR?
The specialist format is well established at comparable infectious disease and diagnostics events, and FutureDx applies it to a deliberately small, senior, validated room. Being first also means owning the association with the UK’s dedicated diagnostics summit as AMR rises up the agenda.
When and where is FutureDx Summit 2026 held?
FutureDx Summit 2026 runs across two days on 27 and 28 October 2026 in London, UK, with a drinks reception on Day 1.
Reach the AMR audience
Get In Front of the Resistance Decision-Makers
Send your details and a senior member of the team replies with the audience breakdown, how your AMR solution fits the agenda, the packages, and pricing.
- The microbiologists and stewardship leads who adopt AMR testing
- Pre-arranged meetings with the buyers you choose
- A reply from a person, not an autoresponder
P.S. Compare the sponsorship packages or the 1:1 Meetings programme.
An Antimicrobial Resistance Diagnostics Conference Track
Is FutureDx an antimicrobial resistance diagnostics conference?
Yes. FutureDx Summit 2026 runs an antimicrobial resistance diagnostics conference track covering AMR detection, rapid resistance testing and stewardship. London, 27–28 October 2026.
What infectious disease conference sponsorship opportunities are available?
FutureDx Summit 2026 offers infectious disease conference sponsorship opportunities across AMR, sepsis and molecular diagnostics: exhibition, speaking and 1:1 meetings with NHS buyers. London, 27–28 October 2026.